SAKAR
Sakar Healthcare Limited (SAKAR) Stock Analysis
Sakar Healthcare Limited manufactures pharmaceutical formulations including tablets, capsules, and liquids for domestic and export markets. It supplies generic medicines across therapeutic categories to distributors and institutions. The company operates WHO-GMP compliant manufacturing facilities. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹961.70
-4.92% 1W | +190.40% 52W
Market Cap
2.1k CR
P/E Ratio
69.9
52W High
₹1229.8
52W Low
₹350.1
Div. Yield
0%
Beta
0.4
50 DMA
₹1017.4
200 DMA
₹730.6
Profit Margin
13.3%
Inst. Own.
0%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 39 | 34 | 37 | 43 | 41 | 43 | 43 | 50 | 53 | 58 | 70 | 71 | 73 |
| Expenses | 30 | 25 | 28 | 32 | 30 | 31 | 32 | 35 | 40 | 46 | 52 | 45 | 52 |
| Operating Profit | 9 | 9 | 9 | 11 | 11 | 12 | 12 | 16 | 13 | 11 | 19 | 26 | 21 |
| OPM % | 23% | 27% | 24% | 25% | 26% | 27% | 27% | 31% | 24% | 20% | 26% | 37% | 29% |
| Other Income | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 |
| Interest | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 4 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 5 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 7 |
| Profit before tax | 4 | 4 | 3 | 5 | 5 | 5 | 5 | 6 | 5 | 5 | 11 | 18 | 15 |
| Tax % | 28% | 13% | 31% | 35% | 49% | 6% | 17% | 8% | 13% | 15% | 6% | 39% | 29% |
| Net Profit | 3 | 4 | 2 | 3 | 2 | 5 | 5 | 6 | 5 | 5 | 10 | 11 | 10 |
| EPS in Rs | 1.49 | 1.70 | 0.95 | 1.43 | 1.11 | 2.21 | 2.06 | 2.62 | 2.10 | 2.04 | 4.61 | 4.95 | 4.62 |
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 83 | 95 | 128 | 133 | 153 | 178 | 251 | 272 |
| Expenses | 63 | 72 | 99 | 100 | 115 | 128 | 182 | 195 |
| Operating Profit | 20 | 23 | 29 | 33 | 38 | 50 | 69 | 77 |
| OPM % | 24% | 24% | 23% | 25% | 25% | 28% | 27% | 28% |
| Other Income | 2 | 1 | 2 | 5 | 3 | 1 | 2 | 3 |
| Interest | 2 | 2 | 3 | 6 | 8 | 9 | 8 | 7 |
| Depreciation | 7 | 8 | 10 | 15 | 18 | 21 | 24 | 25 |
| Profit before tax | 12 | 13 | 19 | 17 | 16 | 22 | 40 | 49 |
| Tax % | 21% | 19% | 20% | 24% | 27% | 19% | 23% | |
| Net Profit | 10 | 11 | 15 | 13 | 12 | 18 | 30 | 36 |
| EPS in Rs | 6.43 | 6.84 | 8.90 | 6.70 | 5.37 | 7.97 | 13.70 | 16.22 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 24.0% | 22.0% | – |
| Profit CAGR | 34.0% | 23.0% | – |
Shareholding Pattern
Promoters52.86%
FIIs13.31%
DIIs11.43%
Public22.41%
Promoters52.86%
FIIs13.05%
DIIs11.36%
Public22.73%
Promoters52.86%
FIIs12.94%
DIIs11.32%
Public22.87%
Promoters52.52%
FIIs12.13%
DIIs11.37%
Public23.98%
Promoters51.70%
FIIs12.34%
DIIs11.92%
Public24.04%
Promoters60.72%
FIIs15.74%
Public23.54%
Promoters53.15%
FIIs13.52%
DIIs10.62%
Public22.71%
Promoters53.58%
FIIs13.61%
DIIs10.97%
Public21.85%
Promoters52.86%
FIIs12.94%
DIIs11.32%
Public22.87%
Promoters51.70%
FIIs12.34%
DIIs11.92%
Public24.04%
SAKAR
Holdings Analysis
Key strengths & risk signals
73
Overall
73
Fundamental
73
Technical
Risks (3)
OVERVALUED! PEG of 3.04 means expensive relative to growth rate.
RECOVERY MODE! Current price (961.7) above 200-day but below 50-day.
WEAK MOMENTUM! Limited price growth - -4.9% (1 week), -13.0% (1 month), 9.6% (3 months).
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (1017.4) is above 200-day average (730.6) - positive signal.
EXCELLENT YEAR! Stock gained 190.4% in the last year.
LOW VOLATILITY! Beta of 0.40 - stable stock, less market risk.
Fundamental & Technical Analysis
73Overall
73Fundamental
73Technical
Fundamental Breakdown
Growth Quality
30/30
Revenue CAGR: 22.0% (EXCELLENT, 15/15). Profit CAGR: 23.0% (EXCELLENT, 15/15).
Profit Margin
5/10
DECENT EFFICIENCY! 13.3% profit margin - acceptable profitability.
PEG Valuation
3/10
OVERVALUED! PEG of 3.04 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
8/10
LOW DEBT! D/E of 0.30 - strong balance sheet.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 23.54% public ownership - balanced ownership structure.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (1017.4) is above 200-day average (730.6) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (961.7) above 200-day but below 50-day.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
10/10
EXCELLENT YEAR! Stock gained 190.4% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 179,451 vs down days: 123,694. Ratio: 1.45x
RSI
3/5
NEUTRAL! RSI at 41.6 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 69.5% of 52W range - positive territory.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -4.9% (1 week), -13.0% (1 month), 9.6% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.40 - stable stock, less market risk.
SAKAR
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-03 | Concall PDF | |
| Q4FY262026-05-22 | Concall PDF | |
| Q3FY262026-02-17 | Concall PDF | |
| Q2FY262025-11-17 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SAKAR | ₹961.70 | 69.9 | 13.3% | 22.0% | 23.0% | +190.4% | 73 | BREAKDOWN | +112.8% | -9.1% | +38.5% | +2.7% |
| SYNCOMF | ₹21.90 | 23.4 | 17.2% | 29.4% | 56.2% | +31.7% | 79 | APPROACHING SUPPORT | +57.0% | -1.6% | +7.4% | -7.3% |
| VENUSREM | ₹1,719.50 | 22.4 | 13.4% | 11.6% | 57.0% | +264.9% | 74 | BREAKDOWN | +126.2% | +85.5% | +31.2% | +43.9% |
| HESTERBIO | ₹2,236.50 | 13.9 | 41.6% | 7.7% | 27.8% | +25.9% | 77 | BOUNCE FROM SUPPORT | +491.5% | +506.3% | -8.2% | -22.9% |
| WINDLAS | ₹917.40 | 29.3 | 7.1% | 20.7% | 16.0% | -1.1% | 73 | BREAKDOWN | 0.0% | +10.6% | +18.1% | +4.0% |
| INDOCO | ₹245.70 | 767.7 | 0.3% | 3.0% | – | -15.5% | 58 | BREAKDOWN | -281.6% | -400.9% | +8.2% | +2.3% |
| BETA | ₹1,783.00 | 26.3 | 11.1% | 19.2% | 10.5% | -2.7% | 68 | CONSOLIDATING DOWN | +35.0% | +75.6% | +25.2% | +33.5% |
| HIKAL | ₹215.60 | – | -1.9% | -5.4% | – | -9.8% | 53 | BREAKDOWN | -67.0% | -151.4% | +7.7% | -22.7% |
Data from TradeAlone · Updated daily
SAKAR News
